Kidney Week

Abstract: TH-PO453

Redefining Overweight and Obesity (OW/OB) in a Large Cohort of Patients with ADPKD

Session Information

• Cystic Kidney Diseases: Clinical Assessment and Therapeutic Directions
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

• 1201 Genetic Diseases of the Kidneys: Cystic

Authors

• Carriazo Julio, Sol Maria, University Health Network, Toronto, Ontario, Canada

Sol Maria Carriazo Julio, MD

• Dehkharghanian, Taher, University Health Network, Toronto, Ontario, Canada

Taher Dehkharghanian, MD, MSc

• Miranda Cam, Mauricio Alejandro, University Health Network, Toronto, Ontario, Canada

Mauricio Alejandro Miranda Cam, MD

• Sarie, Yasmina, University of Toronto, Toronto, Ontario, Canada

Yasmina Sarie

• Song, Xuewen, University of Toronto, Toronto, Ontario, Canada

Xuewen Song, PhD

• Kline, Timothy L., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Timothy L. Kline, MS, PhD

• Khowaja, Saima, University Health Network, Toronto, Ontario, Canada

Saima Khowaja

• Khalili, Korosh, University Health Network, Toronto, Ontario, Canada

Korosh Khalili, MD

• Pei, York, University Health Network, Toronto, Ontario, Canada

York Pei, MD, FASN

Background

Emerging data indicate OW/OB are risk factors for accelerated progression in ADPKD patients. Thus, an accurate diagnosis is crucial to implement appropriate therapeutic measures and avoid unnecessary treatments if not indicated. The traditional BMI formula used to define OW/OB does not take into account the excess of weight attributed to large cystic kidney and liver in ADPKD. Here we define the prevalence and clinical characteristics of ADPKD patients with OW/OB in a large cohort using a formula recommended by KDIGO

Methods

Cross-sectional analysis of patients with PKD1 and PKD2 mutations from the Toronto PKD Registry who had clinical and MRI measurements of total kidney volume (TKV) and total liver volume (TLV) was performed. BMI was calculated by the formula: weight (kg)/height (m²)), while estimated BMI (eBMI) was calculated with the formula proposed by KDIGO: adjusted body weight (body weight (kg) - TKV (kg) - TLV (kg) + weight of normal kidneys and liver/ height (m²)

Results

Table 1 shows clinical characteristics of the study cohort (n=693) and subgroups defined by eBMI category. The median weight and BMI pre and post adjustment were 73 kg and 25,1 kg/m² and 71.8 kg, and 24,3 kg/m² respectively. A total of 352 (50.7%) patients were initially classified as OW/OB but the number decreased to 314 (45.3%) post adjustment; 10.7% of those initially classified as OW/OB were reclassified as having normal weight, and 80 (11.5%) of the study cohort were classified into a milder BMI category post adjustment

Conclusion

OW/OB are highly prevalent among patients with ADPKD and are associated with worse prognoses. Using eBMI for an accurate diagnosis of OW/OB can help avoid unnecessary treatment for those previously misclassified